Hudson Bay Capital Management
MRVI icon

Hudson Bay Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Hudson Bay Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.4K Buy
+12,400
New +$53.5K ﹤0.01% 1186
2025
Q4 		– Sell
-349,663
Closed -$1M – 1424
2025
Q3 		$1M Sell
349,663
-78,654
-18% -$201K ﹤0.01% 863
2025
Q2 		$1.03M Hold
428,317
– – ﹤0.01% 955
2025
Q1 		$947K Buy
428,317
+213,074
+99% +$842K ﹤0.01% 933
2024
Q4 		$1.17M Buy
215,243
+87,846
+69% +$565K ﹤0.01% 722
2024
Q3 		$1.06M Sell
127,397
-345,396
-73% -$2.99M ﹤0.01% 666
2024
Q2 		$3.39M Sell
472,793
-63
-0% -$544 0.02% 449
2024
Q1 		$4.1M Sell
472,856
-1,197,085
-72% -$8.1M 0.02% 342
2023
Q4 		$10.9M Buy
1,669,941
+1,010,544
+153% +$6.53M 0.07% 168
2023
Q3 		$6.59M Buy
659,397
+416,876
+172% +$4.58M 0.05% 230
2023
Q2 		$3.01M Buy
+242,521
New +$3.27M 0.02% 423
2021
Q4 		– Sell
-90,000
Closed -$4.42M – 1161
2021
Q3 		$4.42M Buy
+90,000
New +$4.39M 0.06% 394

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Hudson Bay Capital Management's MRVI Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 12,400 shares worth $77.4K. The stake represents ﹤0.01% of the portfolio and ranks #1186 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in MRVI as recently as Q3 2025.

Hudson Bay Capital Management first reported a position in MRVI in Q3 2021 and has held it in 12 quarters since. The position peaked at $10.9M in Q4 2023. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Hudson Bay Capital Management held 12,400 shares of Maravai LifeSciences worth $77.4K as of Q2 2026.
  • Maravai LifeSciences was a new Hudson Bay Capital Management position in Q2 2026.
  • Maravai LifeSciences made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1186 holding.
  • Hudson Bay Capital Management first reported a position in Maravai LifeSciences in Q3 2021 and has held it in 12 quarters since.
  • Hudson Bay Capital Management's Maravai LifeSciences position peaked at $10.9M in Q4 2023.
  • 177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.